Having established that the co-IP protocol was effective in pulling down Kpnβ1, immunoprecipitation coupled to mass spectrometry (IP-MS) was next performed in order to identify the binding partners of Kpnβ1 in cancer and non-cancer cells. The gene discussed is KPNB1; the disease is cancer.